
Keith Loria
Keith Loria is a contributing writer to Medical Economics.
Articles by Keith Loria




Some orthopedic surgeons have been reluctant to perform total hip arthroplasty on people with HIV/AIDS. Researchers at UT Southwestern Medical Center found no additional risks from HIV per se.

The company-sponsored study compared Sunlenca (lenacapavir) with Rukobia (fostemsavir) and Trograzo (ibalizumab).

When addressing errors, researchers focused on the individual who made the error and retraining. Lead author Fatima Laher says attention should be shifted to root cause analysis and process improvement.

University of North Carolina researchers found stable and replication-competent HIV in the microglia in the brain even in people with HIV who had been taking antiretroviral therapy for a long time.

Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.


Cannabis may accentuate the effects of HIV on the brain or perhaps may mitigate them because of its anti-inflammatory properties.

Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.

‘Yes, PrEP is very important and very useful, but its use is complemented extremely by HIV treatment, so you really have to do both,’ says researcher.


Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.

A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.

A Kaiser Permanente study shows a close link between HIV RNA levels and low CD4 counts and the risk of heart failure.

Stem cell transplants are not being proposed as treatments for HIV, but this case and a handful of others offer promising confirmation that HIV is not entirely incurable.

The known benefits of antiretroviral therapy (ART) in pregnant persons living with HIV outweigh the risks, which include low-birth weight and metabolic complications for the pregnant person, says the lead author of a review article ART and adverse outcomes published in the New England Journal of Medicine.

Researchers report positive result from a phase 1 trial that show the presence of the antiviral medication in rectal tissue.


Uptake of pre-exposure prophylaxis (PrEP) has been slow. A survey shows that safety and side effects are the top concerns.

Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.

Tulane University researchers are studying whether dysregulation of the oral microbiome might affect HIV outcomes. They are using rhesus monkeys and SIV infection as a model.

The researchers have several suggestions for how harm from screening should be reported in screening guidelines.

Results of research by Swiss investigators show effector memory T cells bounce back quickly after autologous hematopoietic stem cell transplantation.

Florida has among the largest populations of people living with HIV in the country. We spoke with a clinician with 40 years of experience taking care of Floridians with HIV.

Research results published in Cell Reports implicate the Nef protein as a possible cause of disease-causing inflammation that persists even when an HIV infection is controlled.

HIV hides out and replicates in the spleen, the lymph nodes and other reservoirs. Emmanuel Okala hopes to develop nanotechnology that will flush it out.

University of Arkansas researchers added to the understanding of how anxiety affects sleep with research that looked for associations between anxiety and bedtime procrastination and other patterns of poor sleep.

